CDMO Blog

close

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies?
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant
CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)
What is a Bioreactor and How is it Used in Cell and Gene Therapy?
12 May 2021

How CCRM's Unique Approach Enables Client Success

Outsourcing to a contract development and manufacturing organization (...

20 Jan 2021

Solving the Technical Challenges in Gene Editing of Induced Pluripotent Stem Cells

In a previous post we provided an overview of induced pluripotent stem...

17 Dec 2020

Five Tips to Help Maximize Your Cell and Gene Therapy Budget

Developing cell and gene therapies (CGTs), from discovery to commercia...

11 Dec 2020

4 Tips from the Experts: How to Tighten Your Timeline from Development to Trial

Responsibly moving a cell or gene therapy forward as quickly as possib...

10 Jan 2020

Road to success: Understanding Good Laboratory Practice for cell and gene therapies

Good Laboratory Practice (GLP) studies are essential for generating no...

30 Oct 2019

Considerations for the Use of Stable Producer Lines in the Manufacturing of Lentiviral Vectors

In an introductory post on lentiviral vector (LVV) manufacturing for c...

22 Oct 2019

How Can a Contract Development and Manufacturing Organization (CDMO) Advance a Cell & Gene Therapy Product?

  Making the Decision to Engage a CDMO

Tell us what you thought about this post.